OTCMKTS:CHCR

Advanzeon Solutions Competitors

$0.10
+0.00 (+2.04 %)
(As of 04/9/2021 11:17 AM ET)
Add
Compare
Today's Range
$0.07
Now: $0.10
$0.10
50-Day Range
$0.09
MA: $0.10
$0.12
52-Week Range
$0.02
Now: $0.10
$0.37
Volume62,600 shs
Average Volume24,261 shs
Market Capitalization$11.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76

Competitors

Advanzeon Solutions (OTCMKTS:CHCR) Vs. RVPH, BLPH, CYTH, NLSP, JUPW, and FSTX

Should you be buying CHCR stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Advanzeon Solutions, including Reviva Pharmaceuticals (RVPH), Bellerophon Therapeutics (BLPH), Cyclo Therapeutics (CYTH), NLS Pharmaceutics (NLSP), Jupiter Wellness (JUPW), and F-star Therapeutics (FSTX).

Advanzeon Solutions (OTCMKTS:CHCR) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Reviva Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanzeon Solutions-1,131.46%N/A-244.73%
Reviva PharmaceuticalsN/A-13.34%-1.36%

Risk and Volatility

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Earnings and Valuation

This table compares Advanzeon Solutions and Reviva Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A
Reviva PharmaceuticalsN/AN/A$620,000.00N/AN/A

Reviva Pharmaceuticals has lower revenue, but higher earnings than Advanzeon Solutions.

Institutional & Insider Ownership

64.1% of Reviva Pharmaceuticals shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 20.6% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Advanzeon Solutions and Reviva Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanzeon Solutions0000N/A
Reviva Pharmaceuticals0000N/A

Summary

Reviva Pharmaceuticals beats Advanzeon Solutions on 5 of the 8 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Bellerophon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanzeon Solutions-1,131.46%N/A-244.73%
Bellerophon TherapeuticsN/A-75.84%-55.16%

Volatility and Risk

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500.

Valuation and Earnings

This table compares Advanzeon Solutions and Bellerophon Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A
Bellerophon TherapeuticsN/AN/A$-13,270,000.00($2.95)-1.65

Advanzeon Solutions has higher revenue and earnings than Bellerophon Therapeutics.

Institutional and Insider Ownership

40.2% of Bellerophon Therapeutics shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 38.5% of Bellerophon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Bellerophon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanzeon Solutions0000N/A
Bellerophon Therapeutics00403.00

Bellerophon Therapeutics has a consensus price target of $26.50, suggesting a potential upside of 444.15%. Given Bellerophon Therapeutics' higher possible upside, analysts clearly believe Bellerophon Therapeutics is more favorable than Advanzeon Solutions.

Summary

Bellerophon Therapeutics beats Advanzeon Solutions on 6 of the 10 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanzeon Solutions-1,131.46%N/A-244.73%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Volatility and Risk

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.

Valuation and Earnings

This table compares Advanzeon Solutions and Cyclo Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A
Cyclo Therapeutics$1.01 million45.61$-7,530,000.00N/AN/A

Advanzeon Solutions has higher earnings, but lower revenue than Cyclo Therapeutics.

Institutional and Insider Ownership

2.4% of Cyclo Therapeutics shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Cyclo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanzeon Solutions0000N/A
Cyclo Therapeutics00103.00

Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 241.53%. Given Cyclo Therapeutics' higher possible upside, analysts clearly believe Cyclo Therapeutics is more favorable than Advanzeon Solutions.

Summary

Cyclo Therapeutics beats Advanzeon Solutions on 7 of the 11 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanzeon Solutions-1,131.46%N/A-244.73%
NLS PharmaceuticsN/AN/AN/A

Valuation and Earnings

This table compares Advanzeon Solutions and NLS Pharmaceutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

NLS Pharmaceutics has lower revenue, but higher earnings than Advanzeon Solutions.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and NLS Pharmaceutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanzeon Solutions0000N/A
NLS Pharmaceutics00303.00

NLS Pharmaceutics has a consensus price target of $10.6667, suggesting a potential upside of 175.62%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Advanzeon Solutions.

Summary

NLS Pharmaceutics beats Advanzeon Solutions on 4 of the 5 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Jupiter Wellness (NASDAQ:JUPW) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Jupiter Wellness, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanzeon Solutions0000N/A
Jupiter Wellness0000N/A

Profitability

This table compares Advanzeon Solutions and Jupiter Wellness' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanzeon Solutions-1,131.46%N/A-244.73%
Jupiter WellnessN/AN/AN/A

Valuation and Earnings

This table compares Advanzeon Solutions and Jupiter Wellness' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A
Jupiter WellnessN/AN/AN/AN/AN/A

Jupiter Wellness has lower revenue, but higher earnings than Advanzeon Solutions.

Summary

Jupiter Wellness beats Advanzeon Solutions on 2 of the 3 factors compared between the two stocks.

F-star Therapeutics (NASDAQ:FSTX) and Advanzeon Solutions (OTCMKTS:CHCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares F-star Therapeutics and Advanzeon Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
F-star TherapeuticsN/A-104.48%-62.16%
Advanzeon Solutions-1,131.46%N/A-244.73%

Earnings and Valuation

This table compares F-star Therapeutics and Advanzeon Solutions' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
F-star TherapeuticsN/AN/A$-24,100,000.00($5.88)-1.77
Advanzeon Solutions$300,000.0039.93$-3,260,000.00N/AN/A

Advanzeon Solutions has higher revenue and earnings than F-star Therapeutics.

Institutional and Insider Ownership

67.8% of F-star Therapeutics shares are owned by institutional investors. 12.7% of F-star Therapeutics shares are owned by insiders. Comparatively, 16.5% of Advanzeon Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

F-star Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Advanzeon Solutions has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for F-star Therapeutics and Advanzeon Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
F-star Therapeutics00403.00
Advanzeon Solutions0000N/A

F-star Therapeutics presently has a consensus target price of $33.50, suggesting a potential upside of 221.50%. Given F-star Therapeutics' higher possible upside, equities analysts clearly believe F-star Therapeutics is more favorable than Advanzeon Solutions.


Advanzeon Solutions Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RVPH
Reviva Pharmaceuticals
0.2$5.02+1.8%$46.35 millionN/A-10.91Analyst Revision
News Coverage
Gap Down
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
1.8$4.87+0.4%$46.22 millionN/A-1.47News Coverage
CYTH
Cyclo Therapeutics
1.8$7.32+4.4%$46.07 million$1.01 million0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87+1.0%$45.59 millionN/A0.00Gap Down
Jupiter Wellness logo
JUPW
Jupiter Wellness
0.0$4.99+4.4%$45.07 millionN/A0.00
F-star Therapeutics logo
FSTX
F-star Therapeutics
1.8$10.42+2.8%$44.98 millionN/A-1.50Analyst Report
Analyst Revision
News Coverage
Sintx Technologies logo
SINT
Sintx Technologies
1.3$1.82+3.3%$44.93 million$690,000.00-0.77Gap Up
Daxor logo
DXR
Daxor
1.6$11.55+2.6%$44.92 millionN/A0.00
Addex Therapeutics logo
ADDXF
Addex Therapeutics
0.6$1.65+0.0%$43.51 millionN/A0.00High Trading Volume
CLNN
Clene
1.9$12.58+2.1%$43.48 millionN/A-28.59
PBLA
Panbela Therapeutics
1.7$4.31+3.2%$43.46 millionN/A0.00
Lixte Biotechnology logo
LIXT
Lixte Biotechnology
0.0$3.20+2.8%$43.32 millionN/A0.00
Acer Therapeutics logo
ACER
Acer Therapeutics
1.3$3.02+1.7%$43.22 millionN/A-1.46
Ceapro logo
CRPOF
Ceapro
0.7$0.57+2.2%$43.17 million$9.71 million28.45News Coverage
Gap Down
PharmaCyte Biotech logo
PMCB
PharmaCyte Biotech
0.5$0.02+0.0%$42.69 millionN/A0.00
PRFX
PainReform
1.0$4.23+3.3%$42.56 millionN/A0.00Gap Up
Mannatech logo
MTEX
Mannatech
1.3$20.52+1.1%$42.46 million$157.73 million6.31
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$3.69+2.2%$41.90 millionN/A-1.22
Histogen logo
HSTO
Histogen
1.6$1.17+4.3%$41.75 million$21.72 million-0.33
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.86+3.3%$41.27 million$1.50 million-1.02
Adial Pharmaceuticals logo
ADIL
Adial Pharmaceuticals
0.4$2.38+1.7%$41.10 millionN/A-3.22Insider Selling
Can-Fite BioPharma logo
CANF
Can-Fite BioPharma
1.4$2.38+1.3%$40.83 million$2.03 million-1.28
HOTH
Hoth Therapeutics
0.5$1.78+7.3%$40.54 millionN/A0.00
CPHI
China Pharma
0.8$0.88+5.7%$40.28 million$10.92 million-1.88
ENTX
Entera Bio
1.2$3.50+6.0%$40.01 million$240,000.00-5.15Gap Up
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.19+6.0%$39.76 million$192.41 million0.76
Sonnet BioTherapeutics logo
SONN
Sonnet BioTherapeutics
1.7$2.26+2.2%$39.68 million$30.14 million0.00
UDHI
Union Dental
0.0$0.16+6.4%$39.21 millionN/A0.00
Biopharmx logo
BPMX
Biopharmx
0.6$2.12+0.5%$38.75 millionN/A0.00News Coverage
ZCMD
Zhongchao
0.0$2.02+0.5%$38.59 million$14.88 million0.00
PMD
Psychemedics
0.8$6.96+1.1%$38.53 million$37.68 million-10.09
Akari Therapeutics logo
AKTX
Akari Therapeutics
1.4$2.41+5.8%$38.22 millionN/A-3.26
FSD Pharma logo
HUGE
FSD Pharma
1.0$1.94+0.0%$37.17 millionN/A0.00News Coverage
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.94+0.0%$37.17 million$190,000.00-0.43
Precipio logo
PRPO
Precipio
1.3$2.05+3.4%$37.17 million$3.13 million0.00
Phio Pharmaceuticals logo
PHIO
Phio Pharmaceuticals
1.8$2.74+1.1%$37.08 million$20,000.00-0.41Gap Up
NovaBay Pharmaceuticals logo
NBY
NovaBay Pharmaceuticals
0.6$0.88+1.1%$36.77 million$6.60 million-2.10
MGT Capital Investments logo
MGTI
MGT Capital Investments
0.5$0.07+0.0%$36.39 million$450,000.000.00Gap Down
AIkido Pharma logo
AIKI
AIkido Pharma
0.6$1.03+4.9%$35.97 million$10,000.000.00
StageZero Life Sciences logo
GNWSF
StageZero Life Sciences
0.5$0.57+10.5%$35.54 million$140,000.00-2.20Analyst Downgrade
TAUG
Tauriga Sciences
0.4$0.13+0.0%$35.25 million$230,000.00-6.40Gap Up
FitLife Brands logo
FTLF
FitLife Brands
0.6$32.00+1.6%$34.91 million$19.50 million0.00News Coverage
CRVW
CareView Communications
0.6$0.25+0.0%$34.85 million$6.29 million-2.78Gap Up
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$8.30+6.9%$34.06 million$24.08 million-0.98Analyst Report
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.25+5.2%$33.61 million$6.57 million-0.01
Immuron logo
IMRN
Immuron
0.5$5.89+1.9%$33.46 million$1.69 million0.00News Coverage
EyeGate Pharmaceuticals logo
EYEG
EyeGate Pharmaceuticals
1.7$4.62+1.5%$32.79 million$2.69 million-2.30News Coverage
ThermoGenesis logo
THMO
ThermoGenesis
1.5$2.74+1.5%$32.64 million$13.05 million-0.60
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.40+1.9%$32.60 million$5.51 million-0.11Analyst Upgrade
News Coverage
Abliva AB (publ) logo
NEVPF
Abliva AB (publ)
0.5$0.12+1.1%$32.33 million$10,000.00-2.37
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.